Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.

Writing Committee for the REMAP-CAP Investigators None. et al, (2023), JAMA, 329, 1183 - 1196

COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

Szubert AJ. et al, (2023), eClinicalMedicine, 56

Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.

Liu Z. et al, (2023), Gastroenterology, 164, 300 - 303.e3

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.

Liu Z. et al, (2023), Lancet Gastroenterol Hepatol, 8, 145 - 156

The effect of TRV027 on coagulation in COVID-19: A pilot randomized, placebo-controlled trial.

Robbins AJ. et al, (2022), Br J Clin Pharmacol

Authors' reply to Upton.

Majeed A. et al, (2022), BMJ, 379

COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.

Alexander JL. et al, (2022), Lancet Gastroenterol Hepatol, 7, 1005 - 1015

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.

Mentzer AJ. et al, (2022), Nat Med

Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV.

Fidler S. et al, (2022), Clin Infect Dis

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines.

Elliott T. et al, (2022), PLoS Pathog, 18

Implementation of covid-19 vaccination in the United Kingdom.

Majeed A. et al, (2022), BMJ, 378

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Ogbe A. et al, (2022), JCI Insight, 7

COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.

Alexander JL. et al, (2022), Lancet Gastroenterol Hepatol, 7, 342 - 352

Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.

Hodgson SH. et al, (2022), Clin Transl Sci, 15, 524 - 534

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.

Pollock KM. et al, (2022), EClinicalMedicine, 44

Comparison of blood and lymph node cells after intramuscular injection with HIV envelope immunogens.

Day S. et al, (2022), Front Immunol, 13

Multicolor Flow Cytometry and High-Dimensional Data Analysis to Probe Complex Questions in Vaccinology.

Cole ME. et al, (2022), 2414, 433 - 447

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.

Feng S. et al, (2021), Nat Med, 27, 2032 - 2040

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

EWER K. et al, (2021), The Lancet

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial

EWER K. et al, (2021), Lancet HIV

Load More

Include forthcoming?